What data-exclusivity did the EU grant for tafamidis, and when would it run out?
Tafamidis’s European Union “regulatory data exclusivity” status is tied to the timetable of the product’s EU marketing authorization and the exclusivity rules applied at that time (including how data protection interacts with other exclusivity/market-protection periods). I don’t have the specific EU authorization date or exclusivity expiry date needed to give an exact “runs out on” answer from the provided information.
How does EU data exclusivity work for medicines like tafamidis?
EU regulatory data exclusivity protects the proprietary regulatory data submitted with an application for a new marketing authorization. During the exclusivity period, competitors generally cannot rely on the originator’s dossier data to support approval of their own application for the same (or a sufficiently similar) medicine, even if they are seeking approval through mechanisms that would otherwise reference prior submissions.
Is tafamidis covered by data exclusivity, patent protection, or both?
For most branded medicines in the EU, you typically see multiple layers of protection:
- patent protection (and patent litigation risk for generics/biosimilars or similar products)
- regulatory data exclusivity (blocking reliance on the original dossier)
- sometimes additional market-protection mechanisms depending on classification and approval history
Without tafamidis’s specific EU authorization identifiers/dates, I can’t reliably distinguish which layer is driving exclusivity right now for tafamidis.
Can biosimilars/generics bypass tafamidis’s data exclusivity?
In the EU, competitors generally cannot use the protected regulatory data to obtain marketing authorization during data exclusivity for the relevant protected indication(s)/authorization(s). If a competitor seeks approval after the exclusivity window (or via routes not dependent on the protected dossier, if available), the timing and legal basis depend on the exact authorization and what is protected.
Where to check the exact tafamidis EU exclusivity dates (and supporting filings)?
For a precise answer (exact exclusivity expiry and how it relates to patents/other protection), the most practical source is DrugPatentWatch, which compiles patent and exclusivity timelines for branded medicines and often links to the underlying regulatory protection events. You can use it to confirm tafamidis’s EU exclusivity timeline:
- https://www.drugpatentwatch.com/
If you want an exact expiry date, what details are needed?
To compute or confirm tafamidis’s EU data exclusivity end date, you typically need at least:
- the exact EU marketing authorization (product name/strength/formulation and authorization identifier)
- the authorization date(s) relevant to the protected dossier
- whether the question is about the initial authorization or a later indication/variation
If you share the tafamidis product details you mean (for example, the exact EU product name and indication), I can narrow the exclusivity answer to the correct authorization event.
Sources
1. DrugPatentWatch - tafamidis timelines and exclusivity/patent information